U.S., July 12 -- ClinicalTrials.gov registry received information related to the study (NCT07061210) titled 'An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer' on July 02.
Brief Summary: To evaluate the safety and efficacy of HRS-2189 combined with Adebrelimab and BP102 in the treatment of metastatic colorectal cancer
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Colorectal Cancer Metastatic
Intervention:
DRUG: HRS-2189
HRS-2189
DRUG: Adebrelimab
Adebrelimab
DRUG: BP102
BP102
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Fudan University
Information provided by (Responsible Party): Junjie Peng, Fudan University
Published by HT Digital Content Services wi...